Background:
- Estrogen receptor (ER) can activate MAPK signaling but the contribution of the two classical receptors, ER-alpha (ESR1) and ER-beta (ESR2), is unclear.
- Past trials targeting ER and EGFR in NSCLC lacked efficacy.
- We evaluated the association of ESR1&2 expression with the genomic landscape and overall survival (OS) in NSCLC.